Technical Analysis for CLVS - Clovis Oncology, Inc.

Grade Last Price % Change Price Change
grade F 14.08 8.73% 1.13
CLVS closed down 3.14 percent on Friday, June 14, 2019, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical CLVS trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 8.73%
Oversold Stochastic Weakness 8.73%
Narrow Range Bar Range Contraction 5.31%
NR7 Range Contraction 5.31%
Wide Bands Range Expansion 5.31%
Oversold Stochastic Weakness 5.31%
Wide Bands Range Expansion 7.48%
Down 3 Days in a Row Weakness 7.48%
Oversold Stochastic Weakness 7.48%
Spinning Top Other 2.55%

Older signals for CLVS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Biopharmaceutical Chemical Compounds Disease Organic Compounds Drug Discovery Breast Cancer Non Small Cell Lung Cancer Lung Cancer Treatment Of Non Small Cell Lung Cancer Epidermal Growth Factor Receptor Lactams Indoles Gastrointestinal Stromal Tumor Heterocyclic Compounds
Is CLVS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 50.0
52 Week Low 11.5
Average Volume 1,349,708
200-Day Moving Average 22.9082
50-Day Moving Average 18.4618
20-Day Moving Average 15.2475
10-Day Moving Average 14.173
Average True Range 0.8983
ADX 49.33
+DI 6.9609
-DI 32.6571
Chandelier Exit (Long, 3 ATRs ) 16.7751
Chandelier Exit (Short, 3 ATRs ) 15.4449
Upper Bollinger Band 17.9834
Lower Bollinger Band 12.5116
Percent B (%b) 0.08
BandWidth 35.886539
MACD Line -1.5275
MACD Signal Line -1.4638
MACD Histogram -0.0637
Fundamentals Value
Market Cap 632.45 Million
Num Shares 48.8 Million
EPS -8.90
Price-to-Earnings (P/E) Ratio -1.46
Price-to-Sales 167.14
Price-to-Book 10.56
PEG Ratio 0.12
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.90
Resistance 3 (R3) 13.93 13.66 13.74
Resistance 2 (R2) 13.66 13.42 13.64 13.68
Resistance 1 (R1) 13.30 13.27 13.17 13.27 13.63
Pivot Point 13.03 13.03 12.96 13.01 13.03
Support 1 (S1) 12.67 12.79 12.54 12.64 12.27
Support 2 (S2) 12.40 12.64 12.38 12.22
Support 3 (S3) 12.04 12.40 12.16
Support 4 (S4) 12.01